1901 West 47th Place
Kansas City, KS 66205
United States
913 942 2300
https://www.cingulate.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 13
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Shane J. Schaffer Pharm.D., PharmD | CEO & Chairman of the Board | 491,96k | N/A | 1975 |
Dr. Laurie A. Myers M.B.A., Ph.D. | Executive VP & COO | 415,17k | N/A | 1957 |
Dr. Matthew N. Brams M.D. | Executive VP & Chief Medical Officer | 244,79k | N/A | 1964 |
Ms. Jennifer L. Callahan CPA | Senior VP, CFO & Secretary | N/A | N/A | 1971 |
Dr. Raul R. Silva M.D. | Executive VP & Chief Science Officer | N/A | N/A | 1958 |
Thomas Dalton | Vice President of Investor & Public Relations | N/A | N/A | N/A |
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
El ISS Governance QualityScore de Cingulate Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.